Related Experiment Videos
Cephalosporin therapeutics for intensive care infections
1Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201-2021.
Abstract:
Third generation cephalosporins are valuable agents in the ICU setting because of their broad spectrum of activity, in vitro potency against the Gram-negative bacilli commonly isolated in the ICU, and excellent penetration into most body sites. Multiresistant organisms may emerge as a result of widespread injudicious use of these agents, and this possibility is of special concern since these organisms may be associated with higher mortality rates. Combination therapy may be superior to monotherapy in severely ill patients with Gram-negative bacteremia. Double-beta lactam therapy has been efficacious in selected patients, although this regimen has several theoretical disadvantages. When third-generation cephalosporins are used for Gram-negative rod bacteremia in the ICU, combination therapy with an aminoglycoside should be considered.
Insights
Third generation cephalosporins are effective in ICUs but injudicious use can lead to multidrug-resistant organisms. Combination therapy, particularly with aminoglycosides, is recommended for Gram-negative rod bacteremia in critically ill patients.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pharmacology
Background:
- Third-generation cephalosporins offer broad-spectrum activity and good tissue penetration, making them vital in intensive care units (ICUs).
- The emergence of multidrug-resistant organisms (MDROs) due to overuse of these agents is a significant concern, potentially increasing mortality.
- Monotherapy may be less effective than combination therapy for severe Gram-negative bacteremia in ICU patients.
Purpose of the Study:
- To evaluate the role and optimal use of third-generation cephalosporins in the ICU.
- To discuss the implications of multidrug-resistant organisms in the context of cephalosporin use.
- To compare monotherapy versus combination therapy for Gram-negative bacteremia in critically ill patients.
Main Methods:
- Review of existing literature on third-generation cephalosporins in ICU settings.
- Analysis of antimicrobial resistance patterns and their impact on treatment outcomes.
- Discussion of therapeutic strategies, including monotherapy and combination regimens.
Main Results:
- Third-generation cephalosporins demonstrate high in vitro potency against common Gram-negative bacilli in ICUs.
- Widespread use raises concerns about the emergence of MDROs, associated with higher mortality.
- Combination therapy, especially double-beta lactam regimens, shows efficacy in select cases, though with theoretical drawbacks.
Conclusions:
- Combination therapy with an aminoglycoside should be considered when using third-generation cephalosporins for Gram-negative rod bacteremia in the ICU.
- Judicious use of third-generation cephalosporins is crucial to mitigate the development of antimicrobial resistance.
- Further research into optimal combination therapies for severe Gram-negative infections in ICUs is warranted.